These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 33441294)
1. Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Hellmann MD; Bivi N; Calderon B; Shimizu T; Delafontaine B; Liu ZT; Szpurka AM; Copeland V; Hodi FS; Rottey S; Aftimos P; Piao Y; Gandhi L; Galvao VR; Leow CC; Doi T Clin Cancer Res; 2021 May; 27(10):2773-2781. PubMed ID: 33441294 [TBL] [Abstract][Full Text] [Related]
2. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Harding JJ; Moreno V; Bang YJ; Hong MH; Patnaik A; Trigo J; Szpurka AM; Yamamoto N; Doi T; Fu S; Calderon B; Velez de Mendizabal N; Calvo E; Yu D; Gandhi L; Liu ZT; Galvao VR; Leow CC; de Miguel MJ Clin Cancer Res; 2021 Apr; 27(8):2168-2178. PubMed ID: 33514524 [TBL] [Abstract][Full Text] [Related]
3. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798 [No Abstract] [Full Text] [Related]
4. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377 [TBL] [Abstract][Full Text] [Related]
5. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232. Villa-Ruano N; Guerrero-González T; Gómez-Conde E; Perez-Santos M Expert Opin Ther Pat; 2020 Oct; 30(10):723-727. PubMed ID: 32787475 [TBL] [Abstract][Full Text] [Related]
6. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673 [TBL] [Abstract][Full Text] [Related]
7. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models. Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647 [TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554 [TBL] [Abstract][Full Text] [Related]
9. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
10. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors. Hollebecque A; Chung HC; de Miguel MJ; Italiano A; Machiels JP; Lin CC; Dhani NC; Peeters M; Moreno V; Su WC; Chow KH; Galvao VR; Carlsen M; Yu D; Szpurka AM; Zhao Y; Schmidt SL; Gandhi L; Xu X; Bang YJ Clin Cancer Res; 2021 Dec; 27(23):6393-6404. PubMed ID: 34465599 [TBL] [Abstract][Full Text] [Related]
11. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814 [TBL] [Abstract][Full Text] [Related]
12. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478 [TBL] [Abstract][Full Text] [Related]
13. Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors. Papadopoulos KP; Lakhani N; Falchook GS; Riley G; Baeck J; Brown KS; Gordon G; Le L; Wang JS Cancer Immunol Immunother; 2021 Mar; 70(3):763-772. PubMed ID: 32989552 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of pembrolizumab in patients with advanced tumors. van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089 [TBL] [Abstract][Full Text] [Related]
16. A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance. Yap TA; LoRusso PM; Wong DJ; Hu-Lieskovan S; Papadopoulos KP; Holz JB; Grabowska U; Gradinaru C; Leung KM; Marshall S; Reader CS; Russell R; Sainson RCA; Seal CJ; Shepherd CJ; Germaschewski F; Gliddon D; Stern O; Young L; Brewis N; Kayitalire L; Morrow M Clin Cancer Res; 2023 Mar; 29(5):888-898. PubMed ID: 36342102 [TBL] [Abstract][Full Text] [Related]
17. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA; Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095 [TBL] [Abstract][Full Text] [Related]
18. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Muik A; Garralda E; Altintas I; Gieseke F; Geva R; Ben-Ami E; Maurice-Dror C; Calvo E; LoRusso PM; Alonso G; Rodriguez-Ruiz ME; Schoedel KB; Blum JM; Sänger B; Salcedo TW; Burm SM; Stanganello E; Verzijl D; Vascotto F; Sette A; Quinkhardt J; Plantinga TS; Toker A; van den Brink EN; Fereshteh M; Diken M; Satijn D; Kreiter S; Breij ECW; Bajaj G; Lagkadinou E; Sasser K; Türeci Ö; Forssmann U; Ahmadi T; Şahin U; Jure-Kunkel M; Melero I Cancer Discov; 2022 May; 12(5):1248-1265. PubMed ID: 35176764 [TBL] [Abstract][Full Text] [Related]
20. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]